---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-25-000136"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:37:57.569003+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports ~80% response and 50% ATD-free remission in Graves' disease trial at six months off-treatment

## Summary
- 80% (17/21) of uncontrolled Graves' patients maintained normal thyroid function six months after stopping batoclimab.
- 50% (8/17) of responders achieved anti-thyroid drug-free remission at six months off-treatment.
- Two registrational trials for lead compound IMVT-1402 in Graves' disease are enrolling with topline data expected in 2027.
- Immunovant will host an investor call on September 3, 2025, at 4:30 p.m. EDT to discuss the data.

## SEC filing metadata
- accession: 0001764013-25-000136
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/0001764013-25-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/imvt-20250903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-25-000136
- JSON: https://secwatch.observer/filing/0001764013-25-000136.json
- Plain text: https://secwatch.observer/filing/0001764013-25-000136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.